)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
CervoMed
CervoMed (CRVO) investor relations material
CervoMed Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary6 Nov, 2026
Executive summary
Neflamapimod is in development for DLB, nfvPPA, stroke recovery and ALS; supportive clinical and biomarker findings underpin the program, with 100mg BID dosing planned.
Q3 net loss narrowed to $5.9M from $7.7M YoY as lower operating expenses more than offset the loss of grant revenue.
September 30 cash, cash equivalents and marketable securities totaled $19.6M; management projected funding through Q3 2027 under its current plan, while financial statements cited substantial doubt and resources insufficient for 12 months from issuance.
Priorities include securing a partner to advance DLB into Phase 3 and delivering clinical and biomarker readouts through 2027.
Financial highlights
Q3 operating expenses were $6.1M, down 27% YoY; operating loss was $6.1M versus $8.0M, and net loss was $5.9M versus $7.7M.
Q3 R&D expense was $3.7M versus $6.0M, mainly reflecting RewinD-LB completion and lower personnel and other costs; G&A was $2.4M versus $2.3M.
Q3 grant revenue was zero versus $0.3M YoY; interest income was $0.2M versus $0.3M.
9M operating expenses were $20.9M, down 13%; net loss was $20.4M versus $18.9M as grant revenue fell to zero from $4.0M.
Q3 net loss per share was $0.39 versus $0.84; 9M net loss per share was $1.77 versus $2.10.
Outlook and guidance
Operating expenses may decline in Q4 as trial count and CMC activity decline; longer-term expenses are expected to rise with development and clinical activity.
R&D spending is expected to increase as larger trials advance; G&A is expected to remain consistent short term while pursuing a strategic partnership, then rise with development and headcount.
Cash at September 30, 2026 was expected to fund planned operating expenses and capital expenditures through Q3 2027 under the current operating plan; the financial statements state resources are insufficient for 12 months from issuance.
Expected milestones: nfvPPA 24-week biomarkers at CTAD in November 2026, initial clinical and additional biomarker data in March 2027, and topline in Q2 2027; RESTORE topline by end-2026 and EXPERTS-ALS first dosing in Q1 2027.
A planned Phase 3 DLB trial depends on available funding, including a strategic partnership.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from CervoMed
- Advancing neflamapimod for DLB with phase III readiness and key data readouts ahead.CRVO
12th Annual Cantor Fitzgerald Global Healthcare Conference - Phase III-ready DLB therapy advances with new formulation and strong regulatory alignment.CRVOH.C. Wainwright 28th Annual Global Investment Conference
- Phase III-ready DLB drug shows strong clinical data; pipeline expands into PPA and ALS.CRVOCanaccord Genuity's 46th Annual Growth Conference
- Raised $20.5M in June 2026 to fund Phase 3 DLB trial and extend cash runway through Q3 2027.CRVOQ2 2026
- Phase II-B trial in early DLB aims for rapid, robust efficacy with biomarker-driven patient selection.CRVOStatus Update
- Biotech targets DLB with novel therapy, raising $20M+ and securing new patent protection.CRVORegistration filing
- Advancing neflamapimod to Phase 3 in DLB, with strong efficacy, financing, and regulatory alignment.CRVO7th Annual HCW Neuro Perspectives Hybrid Conference
- Neflamapimod shows strong, durable efficacy in DLB without AD co-pathology, Phase 3 planned.CRVOCorporate presentation
- Net loss rose to $8.0 million in Q1 2026, with cash runway concerns and pending trial milestones.CRVOQ1 2026
Next CervoMed earnings date
Q4 202612 Mar, 2027
CervoMed
Next CervoMed earnings date
Q4 202612 Mar, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
CervoMed Inc. is a biotechnology company specializing in the development and commercialization of treatments for age-related neurologic disorders. The company’s key focus is on addressing synaptic dysfunction, a critical factor in neurodegenerative diseases. Its lead product candidate, neflamapimod, is an orally administered small molecule designed to treat conditions such as dementia with Lewy bodies, Alzheimer's disease, and frontotemporal dementia by reversing synaptic dysfunction. CervoMed also has additional programs targeting central nervous system disorders in earlier stages of development. The company is headquartered in Boston, Massachusetts, and its shares are listed on the NASDAQ.